No Data
No Data
North China Pharmaceutical (600812.SH): The vitamin series products include the vitamin B12 series and the vitamin C series.
On September 4th, North China Pharmaceutical (600812.SH) stated on the investor interaction platform that the company's vitamin series products include the vitamin B12 series and the vitamin C series. The company will arrange production and operation reasonably based on market demand and its own situation.
Based On Its ROE, Is North China Pharmaceutical Company.Ltd (SHSE:600812) A High Quality Stock?
North China Pharmaceutical (600812.SH): The quadrivalent recombinant influenza virus vaccine (Hansun yeast) has obtained a drug clinical trial approval notice.
On August 23, Gelonghui reported that North China Pharmaceutical (600812.SH) announced that its subsidiary, North China Pharmaceutical Jintan Biotechnology Co., Ltd., received the "Drug Clinical Trial Approval Notice" for the quadrivalent recombinant norovirus vaccine (Hanson yeast) issued by the National Medical Products Administration. The quadrivalent recombinant norovirus vaccine (Hanson yeast) is a recombinant vaccine used to prevent acute gastroenteritis (AGE) caused by Human Norovirus (HuNoV), and is classified as a preventive vaccine.
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
North China Pharmaceutical (600812.SH): The company and its subsidiary companies have received a government subsidy of 2.62 million yuan.
On July 24th, Gelonhui reported that from July 10, 2024 to the date of this announcement, North China Pharmaceutical (600812.SH) and its subsidiaries received a total of RMB 2.62 million in government subsidies related to revenue, accounting for 53.61% of the net income attributable to shareholders of the listed company in 2023.
No Data
No Data